Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid Tumors

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Oncology

Background:

• Small-interfering RNA (siRNA) holds therapeutic potential for modulating disease-related gene expression, particularly in malignant tumors.
• siRNA targeting oncogenes, metastasis, and angiogenesis has shown promise in preclinical and early clinical studies.
• Effective drug delivery remains a significant hurdle for siRNA-based cancer therapies.

Purpose of the Study:

• To review in vivo validated nanoparticle-based siRNA delivery systems for cancer therapy.
• To highlight recent advances in liposomal, polymeric, and inorganic nanoparticle formulations.
• To discuss essential physiochemical properties for efficient siRNA delivery and future research directions.

Main Methods:

• Review of recent scientific literature on nanoparticle-based siRNA delivery systems.
• Analysis of in vivo studies validating different nanoparticle formulations (liposomes, polymers, inorganic).
• Evaluation of physiochemical properties influencing siRNA delivery performance.

Main Results:

• Nanoparticle-based delivery is critical for effective siRNA therapy in tumors.
• Liposomal, polymeric, and inorganic formulations show promise but require optimization.
• Successful delivery necessitates optimization for systemic circulation, tumor penetration, cell entry, and endosomal escape.

Conclusions:

• Optimized nanoparticle design is essential for successful siRNA delivery to tumors.
• Further research should focus on enhancing nanoparticle performance across multiple biological barriers.
• Advancements in nanoparticle formulations are crucial for realizing the therapeutic potential of siRNA in oncology.